BC
RARE icon

Bridgefront Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bridgefront Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$736K Buy
+35,135
New +$791K 0.18% 185
2025
Q4 		– Sell
-9,385
Closed -$282K – 737
2025
Q3 		$282K Buy
+9,385
New +$281K 0.08% 416
2023
Q3 		– Sell
-5,702
Closed -$263K – 568
2023
Q2 		$263K Buy
+5,702
New +$264K 0.14% 301
2021
Q1 		– Sell
-2,490
Closed -$345K – 874
2020
Q4 		$345K Buy
+2,490
New +$295K 0.12% 325

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bridgefront Capital's RARE Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 35,135 shares worth $736K. The stake represents 0.18% of the portfolio and ranks #185 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in RARE as recently as Q3 2025.

Bridgefront Capital first reported a position in RARE in Q4 2020 and has held it in 4 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Bridgefront Capital held 35,135 shares of Ultragenyx Pharmaceutical worth $736K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Bridgefront Capital position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.18% of Bridgefront Capital's portfolio in Q1 2026, its #185 holding.
  • Bridgefront Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 4 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.